TL/DR –
AstraZeneca, Bristol Myers Squibb, and Janssen are presenting opening arguments in their case against the Biden-Harris administration’s Medicare negotiation program at the Third Circuit Court of Appeals. The pharmaceutical industry has launched at least nine lawsuits against the administration and spent over $400 million on lobbying in an effort to undermine the program. However, to date, the industry has lost six of these lawsuits.
Pharmaceutical Giants Present Opening Arguments Against Medicare Negotiation Program
WASHINGTON, DC — Today, AstraZeneca, Bristol Myers Squibb and Janssen initiate their legal battle against the Biden-Harris administration’s Medicare negotiation program at the Third Circuit Court of Appeals. The lawsuit follows the enactment of the Inflation Reduction Act by President Biden. In response to this act, the pharmaceutical industry has launched 9 lawsuits and invested over $400 million in lobbying in a bid to undermine Medicare’s negotiation power. The industry has, however, been unsuccessful in 6 of the previous lawsuits.
—
Read More US Economic News